Xtant Medical Holdings Inc (XTNT) Stock Analysis

AI analysis of Xtant Medical Holdings Inc (XTNT)

Buy

Xtant Medical Holdings Inc is a good buy right now due to its recent exclusive partnership with BioHorizons, which is expected to enhance market penetration and revenue. Additionally, the company has raised its 2026 revenue guidance to between $101 million and $105 million, indicating strong growth potential. The current price is $0.28, significantly below the 52-week high of $0.85, suggesting potential for upside. However, the main risk is the negative earnings per share (EPS) of -0.07 reported in the last quarter, which indicates ongoing financial challenges.

Analyst Ratings (2)

+432.67% upside

Buy

1 Buy

1 Hold

0 Sell

Current: 0.28

Low

1.50

Average

1.50

High

1.50

Lucid Capital

Buy

$1

2026-09-02

Lucid Capital

2026-09-02

Price Target

$1

Buy

BTIG

Buy

$2

2025-11-11

BTIG

2025-11-11

Price Target

$2

Buy

BTIG

Strong Buy

$3

2024-05-16

BTIG

2024-05-16

Price Target

$3

Strong Buy

BTIG

Strong Buy

$2

2023-12-05

BTIG

2023-12-05

Price Target

$2

Strong Buy

Craig-Hallum

Strong Buy

$1.2

2023-07-11

Craig-Hallum

2023-07-11

Price Target

$1.2

Strong Buy

See All Ratings

Valuation Metrics

The current forward P/E ratio for Xtant Medical Holdings Inc (XTNT) is 34.84, compared to its 5-year average forward P/E of -7.92.

Forward P/E

Overvalued

5Y Average P/E

-7.92

Current P/E

34.84

Overvalued

32.05

Undervalued

-47.89

Forward EV/EBITDA

Undervalued

5Y Average EV/EBITDA

18.95

Current EV/EBITDA

-3.66

Overvalued

40.83

Undervalued

-2.93

Forward P/S

Undervalued

5Y Average P/S

0.76

Current P/S

0.38

Overvalued

1.12

Undervalued

0.39

Alphio AI Price Scenarios for XTNT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%XTNT

$0.80

Scenario price

B

Base

Base · 50%XTNT

$0.67

Scenario price

B

Bear

Bear · 25%XTNT

$0.60

Scenario price

Whales holding XTNT

N

Nantahala Capital Management, LLC

+ HoldingXTNT

+10.21%

3M Return

XTNT FAQ — answered by Alphio AI

Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. The Company's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The Company has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Xtant Medical Holdings Inc is a good buy right now due to its recent exclusive partnership with BioHorizons, which is expected to enhance market penetration and revenue. Additionally, the company has raised its 2026 revenue guidance to between $101 million and $105 million, indicating strong growth potential. The current price is $0.28, significantly below the 52-week high of $0.85, suggesting potential for upside. However, the main risk is the negative earnings per share (EPS) of -0.07 reported in the last quarter, which indicates ongoing financial challenges.

2 analysts cover XTNT: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 1.50.